Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPHIR therapy and a fiscal 2025 business update.

Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR, in the U.S. in December 2025 CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ -- Citius Pharmaceuticals ...

Interventional cardiologists say some cases that coders flag and submit to the NCDR aren’t in fact problematic.

Streamline your medical billing process – and receive payment for your services faster – with these suggestions.

Acupuncture is one modality within a much larger medical framework of TCM and related East Asian systems. In daily practice, ...

The World Health Organisation has begun formally incorporating Ayurveda, Siddha, and Unani (ASU) interventions into the ...

The year 2026 is poised to mark a turning point for AI agents in the enterprise. After several years of hype and ...

Background Amyloid transthyretin (ATTR) amyloidosis is a rare, life-threatening disease frequently manifesting with ...

Neuralink’s Blindsight implant has received FDA breakthrough status, aiming to restore sight by stimulating the visual cortex ...

Background Multiple long-term conditions (MLTCs) are common among individuals with heart failure (HF); however, the influence ...

Objectives Given the rapidly evolving therapeutic landscape for type 2 diabetes (T2D) and chronic kidney disease (CKD), this study aimed to characterise the clinical profiles and real-world outcomes ...

In a significant step toward mainstreaming traditional medicine globally, the World Health Organisation (WHO) and India’s ...